Core Viewpoint - China Resources Pharmaceutical (华润医药) reported a revenue of RMB 4.22 billion for Jiangzhong Pharmaceutical in 2025, reflecting a year-on-year decline of 4.87%, while the net profit attributable to shareholders increased by 14.96% to RMB 906 million [1] Group 1: Financial Performance - Jiangzhong Pharmaceutical achieved a revenue of RMB 4.22 billion in 2025, down 4.87% compared to the previous year [1] - The net profit attributable to shareholders reached RMB 906 million, marking a year-on-year increase of 14.96% [1] Group 2: Strategic Initiatives - The company is focusing on strengthening brand development amidst structural adjustments in the industry [1] - Jiangzhong Pharmaceutical is enhancing its marketing strategies, optimizing cost structures, and deepening lean manufacturing practices to improve profitability [1]

Core Viewpoint - Jiangzhong Pharmaceutical reported its preliminary unaudited financial data for the year ending December 31, 2025, indicating a focus on brand building and core business consolidation amid structural industry adjustments [1] Financial Performance - For the year 2025, Jiangzhong Pharmaceutical achieved a revenue of RMB 4.22 billion, representing a year-on-year decline of 4.87% [1] - The net profit attributable to shareholders of the listed company was RMB 906 million, showing a year-on-year increase of 14.96% [1] Strategic Initiatives - The company is enhancing its marketing strategies, optimizing cost structures, and deepening lean manufacturing practices to improve profitability [1] - Jiangzhong Pharmaceutical is focusing on "big single products and strong categories" to solidify its core business foundation [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 江中藥業截至2025年12月31日止年度的主要經營業績預告 於 2026 年 1 月 23 日， 江 中 藥業 公 佈 其 截至 2025 年 12 月 31 日 止 年 度的 未 經 審核 初 步財務資料。 華潤江中藥業股份有限公司（「江中藥業」）為一家於中華人民共和國註冊成立的公 司。江中藥業的股份於上海證券交易所上市。截至本公告日期，江中藥業由華潤 醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）非全資附屬公司 華潤江中製藥集團有限責任公司持有約43.14 %的權益，本集團實際控制江中藥業 約26.12 %並以本公司附屬公司的形式入賬。 – 1 – 於2026年1月23 日，江中藥業公佈其截至2025年12月31日止年度（「本報告期」）的 未經審核初步財務資料 ...

证券之星消息，1月23日中药板块较上一交易日上涨0.28%，*ST长药领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出5.1亿元，游资资金净流出5225.91万元，散户资金净流 入5.62亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000538 | 云南白药 | 2925.96万 | 3.91% | 124.39万 | 0.17% | -3050.36万 | -4.07% | | 002390 | 信邦制药 | 1707.83万 | 9.03% | -877.49万 | -4.64% | -830.34万 | -4.39% | | 600750 江中药业 | | 1112.58万 | 4.76% | 719.17万 | 3.08% | -- 1831. ...

证券代码：600750 证券简称：江中药业 公告编号：2026-003 本公告所载华润江中药业股份有限公司（以下简称"公司"）2025年度主要 财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年度的 定期报告中披露的数据为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标（未经审计） 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 421,950 | 443,545 | -4.87% | | 营业利润 | 119,851 | 102,830 | 16.55% | | 利润总额 | 121,230 | 102,561 | 18.20% | | 归属于上市公司股东的净利润 | 90,612 | 78,819 | 14.96% | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 83,235 | 74,918 | 11.10% | | 基本每股收益（元） | 1.43 | 1.25 | 14.40% | | 加权平均净资产收益率 | 22.74% | 19.58% | 增加 ...

格隆汇1月23日丨江中药业(600750.SH)公布2025年年度业绩快报，报告期内，面对行业结构性调整压 力，公司持续加强品牌打造，围绕"大单品、强品类"夯实核心业务根基；丰富营销策略，强化投入回 报，优化费用结构，并深化精益制造，推进降本增效，助力盈利水平提升。2025年，公司实现营业收入 42.20亿元，同比减少4.87%；实现归属于上市公司股东的净利润9.06亿元，同比增长14.96%。 ...

人民财讯1月23日电，江中药业(600750)1月23日发布业绩快报，2025年公司实现营业总收入42.2亿元， 同比下滑4.87%；归属于上市公司股东的净利润9.06亿元，同比增长14.96%。 转自：证券时报 ...

Core Viewpoint - The article highlights the shift in health and wellness practices among younger generations, moving from traditional methods to modern products like probiotics and nutritional gummies, with Huaren Jiangzhong, a time-honored brand, adapting to this trend [1]. Group 1: Company Overview - Huaren Jiangzhong, a well-established brand with over 50 years of history, is known for its digestive health products [1]. - The company is evolving from traditional products like digestive tablets to modern offerings such as nutritional gummies, reflecting a new development phase [1]. Group 2: Industry Trends - There is a growing trend of "light health" among younger consumers, who prefer convenient and modern health products over traditional remedies [1]. - The article emphasizes that true heritage involves adapting traditional wisdom to contemporary consumer lifestyles, contributing to a healthier society [1].

Core Viewpoint - China Resources Pharmaceutical Group Limited is a leading comprehensive pharmaceutical company in China, ranking among the top three in the industry, with a compound annual growth rate (CAGR) of 7.5% in revenue from 2019 to 2024 [1] Group 1: Pharmaceutical Manufacturing and OTC Business - The company is the largest OTC manufacturer in China, focusing on consumer health products (CHC), with traditional Chinese medicine and health products accounting for nearly 60% of revenue by mid-2025 [1] - The pharmaceutical business is expected to grow at a CAGR of 10.4% from 2022 to 2024, driven by both organic growth and acquisitions [2] - By mid-2025, the revenue from OTC traditional Chinese medicine and chemical OTC products reached 8.7 billion yuan and 2.5 billion yuan, respectively, making up 45% of the pharmaceutical business revenue [1] Group 2: Business Expansion through Acquisitions - The company expanded its business scope through acquisitions, including a 43% stake in Jiangzhong Pharmaceutical in February 2019, enhancing its position in the traditional Chinese medicine sector [2] - Acquisitions of 28% stakes in Kunming Pharmaceutical and Tasly Pharmaceutical in December 2022 and March 2025, respectively, further solidified its leadership in the traditional Chinese medicine industry [2] - The company entered the blood products sector by acquiring a 29% stake in Boya Bio-Pharmaceutical in November 2021 and expanded into medical devices with the acquisition of Nanger Technology in February 2025 [2] Group 3: Pharmaceutical Distribution - The company ranks third in the pharmaceutical distribution industry, with revenue reaching 110 billion yuan in the first half of 2025, following China National Pharmaceutical Group and Shanghai Pharmaceuticals [3] - The distribution business generated 108.3 billion yuan in revenue in the first half of 2025, with medical device revenue growing by 8% to 18 billion yuan [3] - Retail revenue reached 5.5 billion yuan in the first half of 2025, reflecting an 11% year-on-year growth, supported by the establishment of specialized pharmacies and a new retail system [3] Group 4: Financial Projections and Valuation - The company is projected to achieve net profits attributable to ordinary shareholders of 3.49 billion yuan, 3.76 billion yuan, and 4.05 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.0%, 7.9%, and 7.7% [3] - A price-to-earnings (PE) ratio of 8.7 times is assigned for 2026, corresponding to a market value of 35.3 billion Hong Kong dollars, indicating a 24% upside potential from the current market value of 28.5 billion Hong Kong dollars [3]

Group 1 - The company has completed the registration process for a name change from "Jiangzhong Pharmaceutical" to "China Resources Jiangzhong," with the stock code remaining 600750 [1][3] - The name change aims to strengthen brand synergy with China Resources Group and enhance brand recognition and market influence [3][4] - This change marks the full integration of Jiangzhong Pharmaceutical into the China Resources brand system after six years of restructuring since China Resources Group became the controlling shareholder in 2019 [3][4] Group 2 - Jiangzhong Pharmaceutical's revenue for the first three quarters of 2025 was 2.933 billion yuan, a year-on-year decline of 6.28%, with the third quarter showing a more significant drop of 7.59% [4] - The core over-the-counter (OTC) product, Jianwei Jianshi Pian, has seen declining sales, with a 10.65% drop in revenue in the third quarter of 2025 [4][6] - The company is facing intense competition in the OTC market, with numerous similar products available, leading to a significant increase in marketing expenses, which accounted for nearly one-third of revenue [6][5] Group 3 - The company is focusing on developing its prescription drug segment as a potential second growth curve, with a revenue of 790 million yuan in 2024, down 3.5% year-on-year [5][6] - The company has outlined three strategic goals: strengthening OTC products, developing health consumer goods, and expanding the prescription drug segment [6]